Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Is Bristol-Myers Squibb Company BMY Among the Best Pharma Dividend Stocks to Buy In 2024?

January 07, 2025
Bristol-Myers Squibb Company (BMY) is gaining attention as one of the best pharmaceutical dividend stocks to buy in 2024. With a stellar track record and promising future plans, investors are looking at BMY as a potential long-term investment.

Recently, BMY announced its participation in J.P. Morgan's 43rd Annual Healthcare Conference, which further cemented its position as a prominent player in the pharmaceutical industry. The conference provides a platform for BMY to showcase its innovative treatments and pipelines, attracting potential investors who are eager to explore the company's growth opportunities.

BMY has consistently delivered strong financial results, making it an attractive choice for dividend investors. By investing in BMY, shareholders can expect stable dividend payments and potential capital appreciation as the company continues to expand its product portfolio.

However, it is important to note that investing in stocks requires careful analysis and consideration. To get professional insights into the potential movement of BMY stocks, it is recommended to seek advice from experts such as Stocks Prognosis.

In conclusion, Bristol-Myers Squibb Company (BMY) stands out as one of the best pharma dividend stocks to buy in 2024. With its participation in the J.P. Morgan Healthcare Conference and a strong track record, BMY is poised for future growth. Investors looking for promising opportunities in the pharmaceutical sector should consider BMY as a potential investment, and consult with professionals like Stocks Prognosis for their expert insights.
If you want to leave a comment, then you need Login or Register





Other data for BMY

Related data

BMYJuly 31, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.1% Profit Achieved  ~1 min.

On April 16, 2025, QuantWave issued a short forecast signal for BRISTOL-MYERS SQUIBB COMPANY with a price of 48.72 $. Fast forward to July 31, 2025, the target price of 43....


BMYJuly 31, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Forecast Price Target with 10.86% Profit  ~1 min.

QuantWave, an automated forecasting platform, recently achieved a milestone in its prediction accuracy with the successful forecast of BRISTOL-MYERS SQUIBB COMPANY's stock movement....


BMYJune 23, 2025Bristol Myers Squibb NYSE:BMY Set to Revolutionize Cancer Treatment with Breakthrough Drug  ~1 min.

Bristol Myers Squibb Company, a leading pharmaceutical company, is on the verge of revolutionizing cancer treatment with its groundbreaking new drug....


BMYJune 12, 2025BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu  ~1 min.

Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3....


BMYMay 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit  ~2 min.

QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin  ~2 min.

On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Price Target with 9.09% Profit: QuantWave Forecast Success  ~2 min.

On April 23, 2025, QuantWave's forecasting platform generated a short signal for BRISTOL-MYERS SQUIBB COMPANY stock, which was trading at $47.9 at the time....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 12.75% Profit - QuantWave Analysis  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY recently achieved the price target forecast set by QuantWave, resulting in a profitable outcome of 12.75%....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.87% Profit  ~1 min.

On May 5, 2025, QuantWave issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.41. The forecast proved accurate as the price target of $43....


BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.76% Profit  ~1 min.

On April 15, 2025, QuantWave, the automated forecasting platform, issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.35....


BMYJanuary 9, 2025Bristol-Myers Squibb Announces Breakthrough in Cancer Treatment Research  ~2 min.

Bristol-Myers Squibb, a leading pharmaceutical company, has made a major breakthrough in cancer treatment research....


REGNJanuary 29, 2025Regeneron Pharmaceuticals Inc. REGN: A Leader in Biopharmaceutical Innovation  ~2 min.

Regeneron Pharmaceuticals Inc. (REGN) is a biopharmaceutical company known for its pioneering work in developing innovative therapies....


REGNJanuary 2, 2025Regeneron Pharmaceuticals: An Impressive 89% Return Over the Last Five Years  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been a rewarding investment for shareholders, with a solid 89% return over the past five years, according to Yahoo Finance....


REGNJanuary 4, 2025Regeneron Pharmaceuticals Inc.: A Strong Investment Opportunity for Shareholders  ~1 min.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has proven to be a successful investment option for shareholders, with a decent 89% return over the last five years....


GSKJanuary 5, 2025GSK Plc's Strong Returns and Updates on Voting Rights and Capital Structure  ~1 min.

GSK plc, a leading pharmaceutical company, continues to deliver strong returns to its shareholders....